Genital warts and their treatment

Clinical Infectious Diseases

Volumn 28, Issue 1 SUPPL., 1999, Pages

  Beutner, Karl R ^a   Wiley, Dorothy J ^b   Douglas, John M ^b   Tyring, Stephen K ^b   Fife, Kenneth ^b   Trofatter, Kenneth ^b   Stone, Katherine M ^b  

^a Solano Dermatology Associates   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DICHLOROACETIC ACID; FLUOROURACIL; IMIQUIMOD; INTERFERON; PODOPHYLLIN; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID;

ARTICLE; BLEEDING; BURN; CONDYLOMA; CRYOTHERAPY; CURETTAGE; ELECTROSURGERY; ERYTHEMA; FEMALE; HUMAN; LASER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; SEXUALLY TRANSMITTED DISEASE; TOPICAL DRUG ADMINISTRATION; WART VIRUS;

EID: 0033045439     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514722     Document Type: Article

References (126)

1. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-63.
2. de Villiers EM. Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol 1994;186:1-12.
3. Delius H, Hofmann B. Primer-directed sequencing of human papillomavirus types. Curr Top Microbiol Immunol 1994;186:13-31.
4. IARC Working Group on Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses. Vol. 64. Human papillomaviruses: views and expert opinions of an IARC working group on the evaluation of carcinogenic risks to humans, which met in Lyon, 6-13 June 1995. Lyon, France: World Health Organization, International Agency for Research on Cancer, 1995.
5. Gross G, Pfister H, Hagedorn M, Gissmann L. Correlation between human papillomavirus (HPV) type and histology of warts. J Invest Dermatol 1982;78:160-4.
6. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
7. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA: its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984;3:1151-7.
8. Gissmann L. Human papillomavirus DNA in genital tumours. IARC Sci Publ 1984;63:405-11.
9. Munoz N, Bosch F, Shaw KV, et al. The epidemiology of human papillomavirus and cervical cancer. Lyon, France: International Agency for Research on Cancer, 1992:3-23.
10. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group [see comments]. J Natl Cancer Inst 1995;87:796-802.
11. Buschke A, Lowenstein L. Uber carcinomahnliche condylomata acuminata. Klin Wochenschr 1925;4:1726.
12. Boshart M, zur Hausen H. Human papillomaviruses in Buschke-Lowenstein tumors: physical state of the DNA and identification of a tandem duplication in the noncoding region of a human papillomavirus 6 subtype. J Virol 1986;58:963-6.
13. Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy. J Infect Dis 1993;167:824-9.
14. Bellina JH. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol 1983;147:375-8.
15. Ferenczy A. Laser therapy of genital condylomata acuminata. Obstet Gynecol 1984;63:703-7.
16. Syed TA, Khayyami M, Kriz D, et al. Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study. J Mol Med 1995;73:255-8.
17. Armstrong DK, Maw RD, Dinsmore WW, et al. Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Genitourin Med 1996;72:103-7.
18. von Krogh G, Szpak E, Andersson M, Bergelin I. Self-treatment using 0.25%-0.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study. Genitourin Med 1994;70:105-9.
19. von Krogh G, Wikstrom A. Efficacy of chemical and/or surgical therapy against condylomata acuminata: a retrospective evaluation. Int J STD AIDS 1991;2:333-8.
20. Kirby PK, Kiviat N, Beckman A, Wells D, Sherwin S, Corey L. Tolerance and efficacy of recombinant human interferon gamma in the treatment of refractory genital warts. Am J Med 1988;85:183-8.
21. Rader JS, Leake JF, Dillon MB, Rosenshein NB. Ultrasonic surgical aspiration in the treatment of vulvar disease [see comments]. Obstet Gynecol 1991;77:573-6.
22. Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK Jr. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991;77: 735-9.
23. Jensen SL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet 1985;2:1146-8.
24. Schoenfeld A, Ziv E, Levavi H, Samra Z, Ovadia J. Laser versus loop electrosurgical excision in vulvar condyloma for eradication of subclinical reservoir demonstrated by assay for 2′5′ oligosynthetase human papillomavirus. Gynecol Obstet Invest 1995;40:46-51.
25. Panici PB, Scambia G, Perrone L, et al. Oral condyloma lesions in patients with extensive genital human papillomavirus infection. Am J Obstet Gynecol 1992;167:451-8.
26. Monsonego J, Cessot G, Ince SE, Galazka AR, Abdul-Ahad AK. Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum. Genitourin Med 1996;72:111-4.
27. Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer-blind placebo-controlled study. Genitourin Med 1991;67:297 302.
28. Wiltz OH, Torregrosa M, Wiltz O. Autogenous vaccine: the best therapy for perianal condyloma acuminata? Dis Colon Rectum 1995;38: 838-41.
29. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method [see comments]. JAMA 1991;265:472-7.
30. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-8.
31. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991; 83:997.
32. Schultz RE, Miller JW, MacDonald GR, et al. Clinical and molecular evaluation of acetowhite genital lesions in men. J Urol 1990;143: 920-3.
33. Wikstrom A, Hedblad MA, Johansson B, et al. The acetic acid test in evaluation of subclinical genital papillomavirus infection: a comparative study on penoscopy, histopathology, virology and scanning electron microscopy findings. Genitourin Med 1992;68:90-9.
34. Beutner KR, Richwald GA, Wiley DJ, et al. External genital warts: report of the American Medical Association Consensus Conference. Clin Infect Dis 1998: in press.
35. Fitzpatrick J, Gentry R. Nonvenereal diseases of male genitalia. In: Moschella S, Hurley H, eds. Dermatology. 3rd ed. Vol. 1. Philadelphia: WB Saunders, 1992:1013-4.
36. Jakubovic H, Ackerman A. Structure and function of skin: development, morphology, and physiology. In: Moschella S, Hurley HJ, eds. Dermatology. 3rd ed. Vol. 1. Philadelphia: WB Saunders, 1992:64.
37. Gonzalez E. Molluscum contagiosum and other viruses. In: Moschella S, Hurley H, eds. Dermatology. 3rd ed. Vol. 1. Philadelphia: WB Saunders, 1992:1014-5.
38. Koh H, Ghawan J. Tumors of the skin. In: Moschella S, Hurley H, eds. Dermatology. 3rd ed. Vol. 1. Philadelphia: WB Saunders, 1992:1721-808.
39. Gibson L, Perry H. Papulosquamous eruptions and exfoliative dermatitis. In: Moschella S, Hurley HJ, eds. Dermatology. 3rd ed. Vol. 1. Philadelphia: WB Saunders, 1992:629-36.
40. Oriel JD. Sexually transmitted diseases in children: human papillomavirus infection. Genitourin Med 1991;67:394-9.
41. Campion MJ, Greenberg MD, Kazamel TI. Clinical manifestations and natural history of genital human papillomavirus infections. Obstet Gynecol Clin North Am 1996;23:783-809.
42. Armstrong DK, Maw RD, Dinsmore WW, et al. A randomised, double-blind, parallel group study to compare subcutaneous interferon alpha-2a plus podophyllin with placebo plus podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1994;70:389-93.
43. Gissmann L, zur Hausen H. Partial characterization of viral DNA from human genital warts (Condylomata acuminata). Int J Cancer 1980;25: 605-9.
44. Gissmann L, deVilliers EM, zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papilomavirus type 6 DNA. Int J Cancer 1982;29:143-6.
45. Carr G, William DC. Anal warts in a population of gay men in New York City. Sex Transm Dis 1977;4:56-7.
46. Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen JJ. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989;81:1726-31.
47. Baggish MS. Improved laser techniques for the elimination of genital and extragenital warts. Am J Obstet Gynecol 1985;153:545-50.
48. Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986;315:1059-64.
49. Condylomata International Collaborative Study Group. Recurrent condylomata acuminata treated with recombinant interferon alpha-2a: a multicenter double-blind placebo-controlled clinical trial. Acta Derm Venereol 1993;73:223-6.
50. Condylomata International Collaborative Study Group. A comparison of interferon alfa-2a and podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1991;67:394-9.
51. Beutner KR, Conant MA, Friedman-Kien AE, et al. Patient-applied podofilox for treatment of genital warts. Lancet 1989;1:831-4.
52. Duus BR, Philipsen T, Christensen JD, Lundvall F, Sondergaard J. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med 1985;61:59-61.
53. Reid R. The management of genital condylomas, intraepithelial neoplasia, and vulvodynia. Obstet Gynecol Clin North Am 1996;23:917-91.
54. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS. 1993;4: 194-9.
55. Wade TR, Ackerman AB. The effects of resin of podophyllin on condyloma acuminatum. Am J Dermatopathol 1984;6:109-22.
56. Petersen CS, Weismann K. Quercetin and kaempherol: an argument against the use of podophyllin? Genitourin Med 1995;71:92-3.
57. Edwards A, Atma-Ram A, Thin RN. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts. Genitourin Med 1988;64:263-5.
58. Gabriel G, Thin RN. Treatment of anogenital warts. Comparison of trichloracetic acid and podophyllin versus podophyllin alone. Br J Vener Dis 1983;59:124-6.
59. Hellberg D, Svarrer T, Nilsson S, Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Int J STD AIDS. 1995;6:257-61.
60. Khawaja HT. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study [see comments]. Br J Surg 1989;76:1067-8.
61. Lassus A, Haukka K, Forsstrom S. Podophyllotoxin for treatment of genital warts in males: a comparison with conventional podophyllin therapy. Eur J Sex Transm Dis 1984;2:31-3.
62. Potkul RK, Lancaster WD, Kurman RJ, Lewandowski G, Weck PK, Delgado G. Vulvar condylomas and squamous vestibular micropapilloma: differences in appearance and response to treatment. J Reprod Med 1990;35:1019-22.
63. Simmons PD. Podophyllin 10% and 25% in the treatment of ano-genital warts: a comparative double-blind study. Br J Vener Dis 1981;57: 208-9.
64. Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990;66:16-9.
65. Petersen CS, Agner T, Ottevanger V, Larsen J, Ravnborg L. A single-blind study of podophyllotoxin cream 0.5% and podophyllotoxin solution 0.5% in male patients with genital warts. Genitourin Med 1995; 71:391-2.
66. Strand A, Brinkeborn RM, Siboulet A. Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Genitourin Med 1995;71:387-90.
67. Syed TA, Lundin S. Topical treatment of penile condylomata acuminata with podophyllotoxin 0.3% solution, 0.3% cream and 0.15% cream. Dermatology 1993;187:30-3.
68. Syed TA, Lundin S, Ahmad SA. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women: a placebo-controlled, double-blind study. Dermatology 1994;189:142-5.
69. Tyring S, Edwards L, Cherry LK, et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998;134:33-8.
70. von Krogh G, Hellberg D. Self-treatment using a 0.5% podophyllotoxin cream of external genital condylomata acuminata in women: a placebo-controlled, double-blind study. Sex Transm Dis 1992;19:170-4.
71. Baker DA, Douglas JM, Buntin DM, Micha JP, Beutner KR, Patsner B. Topical podofilox for the treatment of condylomata acuminata in women. Obstet Gynecol 1990;76:656-9.
72. Pickering R. Self-treatment of genital warts using Warticon. Br J Sex Med 1989; August:320 4.
73. von Krogh G. Penile condylomata acuminata: an experimental model for evaluation of topical self-treatment with 0.5-1.0% ethanolic preparations of podophyllotoxin for three days. Sex Transm Dis 1981;8: 179-86.
74. von Krogh G. Topical self-treatment of penile warts with 0.5% podophyllotoxin in ethanol for four or five days. Sex Transm Dis 1987;14: 135-40.
75. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9.
76. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134:25-30.
77. Beutner KR, Edwards L, Fox T, Gayoso K, Hougham A, Owens ML. Comparison of the results from two well-controlled clinical trials of topical imiquimod for the treatment of genital/perianal warts. In: Proceedings of a conference of The Society for Investigative Dermatology (Chicago). 1995.
78. Edwards L, Ferenczy A, Eron L, et al. Multicenter safety and efficacy trial evaluating three times per week application of 1% and 5% topical imiquimod for the treatment of genital/perianal warts. In: Proceedings of the International Society for Antiviral Research, 8th International Conference on Antiviral Research (Santa Fe, New Mexico). 1995.
79. Trofatter K, Beutner K, Edwards L, et al. Two vehicle controlled clinical trials of topical imiquimod for the treatment of genital/perianal condylomata acuminata. In: Proceedings of 44th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists. 1996.
80. Spruance S, Kriesel J, Beutner K, et al. Double blind, dose ranging, placebo controlled, multicenter trial of imiquimod cream for the treatment of genital and perianal warts. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995.
81. Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 1993;20:344-5.
82. Eron LJ, Alder MB, O'Rourke JM, Rittweger K, DePamphilis J, Pizzuti DJ. Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon. Genitourin Med 1993;69:91-3.
83. Balsdon MJ. Cryosurgery of genital warts [letter]. Br J Vener Dis 1978; 54:352-3.
84. Bashi SA. Cryotherapy versus podophyllin in the treatment of genital warts. Int J Dermatol 1985;24:535-6.
85. Bergman A, Bhatia NN, Broen EM. Cryotherapy for treatment of genital condylomata during pregnancy. J Reprod Med 1984;29:432-5.
86. Damstra RJ, van Vloten WA. Cryotherapy in the treatment of condylomata acuminata: a controlled study of 64 patients. J Dermatol Surg Oncol 1991;17:273-6.
87. Ghosh AK. Cryosurgery of genital warts in cases in which podophyllin treatment failed or was contraindicated. Br J Vener Dis 1977;53: 49-53.
88. Godley MJ, Bradbeer CS, Gellan M, Thin RN. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med 1987;63:390-2.
89. Douglas JM Jr, Eron LJ, Judson FN, et al. A randomized trial of combination therapy with intralesional interferon alpha 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis 1990;162:52-9.
90. Scott GM, Csonka GW. Effect of injections of small doses of human fibroblast interferon into genital warts: a pilot study. Br J Vener Dis 1979;55:442-5.
91. Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interfcrons administered intralesionally; a double-blind, placebo-controlled trial. Ann Intern Med 1988; 108:675-9.
92. Schwartz DB, Greenberg MD, Daoud Y, Reid R. Genital condylomas in pregnancy: use of trichloroacetic acid and laser therapy. Am J Obstet Gynecol 1988;158:1407-16.
93. Simmons PD, Langlet F, Thin RN. Cryotherapy versus electrocautery in the treatment of genital warts. Br J Vener Dis 1981;57:273-4.
94. McMillan A, Scott GR. Outpatient treatment of perianal warts by scissor excision. Genitourin Med 1987;63:114-5.
95. Reid R. Physical and surgical principles of laser surgery in the lower genital tract. Obstet Gynecol Clin North Am 1991;18:429-74.
96. Reid R. Physical and surgical principles governing carbon dioxide laser surgery on the skin. Dermatol Clin 1991;9:297-316.
97. Condylomata International Collaborative Study Group. Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic interferon-alpha 2a in the treatment of anogenital condylomata acuminatum. J Infect Dis 1993;167:824-9.
98. Davis BE, Noble MJ. Initial experience with combined interferon-alpha 2B and carbon dioxide laser for the treatment of condylomata acuminata. J Urol 1992;147:627-9.
99. Bar-Am A, Shilon M, Peyser MR, Ophir J, Brenner S. Treatment of male genital condylomatous lesions by carbon dioxide laser after failure of previous nonlaser methods. J Am Acad Dermatol 1991;24:87-9.
100. 2-laser treatment of condylomata acuminata. Acta Obstet Gynecol Scand 1984;63:341-3.
101. Petersen C, Bjerring P, Larson J, et al. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin Med 1991;67: 99-102.
102. Reid R, Greenberg MD, Pizzuti DJ, Omoto KH, Rutledge LH, Soo W. Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon. Am J Obstet Gynecol 1992;166:815-20.
103. Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. N Engl J Med 1985;313:784-8.
104. Boot JM, Blog FB, Stolz E. Intralesional interferon alfa-2b treatment of condylomata acuminata previously resistant to podophyllum resin application. Genitourin Med 1989;65:50-3.
105. Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988;259:533-8.
106. Geffen JR, Klein RJ, Friedman-Kien AE. Intralesional administration of large doses of human leukocyte interferon for the treatment of condylomata acuminata. J Infect Dis 1984;150:612-5.
107. Vance JC, Bart BJ, Hansen RC, et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986;122:272-7.
108. Welander CE, Homesley HD, Smiles KA, Peets EA. Intralesional interferon alfa-2b for the treatment of genital warts. Am J Obstet Gynecol 1990;162:348-54.
109. Friedman-Kien A. Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived). Am J Obstet Gynecol 1995;172:1359-68.
110. Swinehart JM, Sperling M, Phillips S, et al. Intralesional fluorouracil/ epinephrine injectable gel for treatment of condylomata acuminata: a phase 3 clinical study. Arch Dermatol 1997;133:67-73.
111. Swinehart J, Skinner R, McCarty J, et al. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med 1997;73:481-7.
112. Swinehart J, Willson C, Lu S, Orenberg E, Korey A. Intralesional accusite (fluorouracil/epinephrine) injectable gel (MPI 5003) for treatment of condylomata acuminata: a two-cycle treatment regime. In: Proceedings of a meeting of The American Academy of Dermatology, 30 July 3 August 1994.
113. Snoeck R, Van Ranst M, Andrei G, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue [letter]. N Engl J Med 1995;333:943-4.
114. Douglas J, Corey L, Conant M, McGuire B, Jaffe H. A phase I/II study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection. In: Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: American Society for Microbiology, 1997.
115. Condylomata International Collaborative Study Group. Recurrent condylomata acuminata treated with recombinant interferon alfa-2a: a multicenter double-blind placebo-controlled clinical trial. JAMA 1991; 265:2684-7.
116. Bonnez W, Oakes D, Bailey-Farchione A, et al. A randomized, double-blind, placebo-controlled trial of systemically administered interferon-alpha, -beta, or -gamma in combination with cryotherapy for the treatment of condyloma acuminatum. J Infect Dis 1995;171:1081-9.
117. Gall SA, Hughes CE, Trofatter K. Interferon for the therapy of condyloma acuminatum. Am J Obstet Gynecol 1985;153:157-63.
118. Gall SA, Constantine L, Koukol D. Therapy of persistent human papillomavirus disease with two different interferon species. Am J Obstet Gynecol 1991;164:130-4.
119. 2-laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial [letter]. Genitourin Med 1996;72:71.
120. Olmos L, Vilata J, Rodriguez Pichardo A, Lloret A, Ojeda A, Calderon MD. Double-blind, randomized clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS. 1994;5:182-5.
121. Reichman RC, Micha JP, Weck PK, et al. Interferon alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy. Antiviral Research 1988;10:41-57.
122. Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis 1990;162:1270-6.
123. von Krogh G. The beneficial effect of 1% 5-fluorouracil in 70% ethanol on therapeutically refractory condylomas in the preputial cavity. Sex Transm Dis 1978;5:137-40.
124. Haye KR. Treatment of condyloma acuminata with 5 percent 5-fluorouracil (5-FU) cream [letter]. Br J Vener Dis 1974;50:466.
125. Krebs HB. Combination of laser plus 5-fluorouracil for the treatment of extensive genital condylomata acuminata. Lasers Surg Med 1988;8: 135-8.
126. Krebs H. Treatment of extensive vulvar condylomata acuminata with topical 5-fluorouracil. South Med J 1990;83:761-4.